Abstract
Drug resistance in leukaemia is a major problem that needs to be addressed. Precision medicine provides an avenue to reduce drug resistance through a personalised treatment plan. It has helped to better stratify patients based on their molecular profile and therefore improved the sensitivity of patients to a given therapeutic regimen. However, therapeutic options are still limited for patients who have already been subjected to many lines of chemotherapy. The process of designing and developing new drugs requires significant resources, including money and time. Drug repurposing has been explored as an alternative to identify effective drug(s) that could be used to target leukaemia and lessen the burden of drug resistance. The drug repurposing process usually includes preclinical studies with drug screening and clinical trials before approval. Although most of the repurposed drugs that have been identified are generally safe for leukaemia treatment, they seem not to be good candidates for monotherapy but could have value in combination with other drugs, especially for patients who have exhausted therapeutic options. In this review, we highlight precision medicine in leukaemia and the role of drug repurposing. Specifically, we discuss the several screening methods via chemoinformatic, in vitro, and ex vivo that have facilitated and accelerated the drug repurposing process.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ALL:
-
Acute Lymphocytic Leukaemia
- AML:
-
Acute Myeloid Leukaemia
- CLL:
-
Chronic Lymphocytic Leukaemia
- CML:
-
Chronic Myeloid Leukaemia
- QSAR:
-
Quantitative Structure-Activity Relationship
- FDA:
-
Food and Drug Administration
- WHO:
-
World Health Organisation
- FAB:
-
French-American-British Association
- BCR:
-
B-cell Receptor
- BTK:
-
Bruton Tyrosine Kinase
- PIK:
-
Phosphoinositide 3-Kinase
References
Abdulmawjood B, Costa B, Roma-Rodrigues C, Baptista PV, Fernandes AR (2021) Genetic biomarkers in chronic myeloid leukemia: what have we learned so far? Int J Mol Sci 22(22):12516. https://doi.org/10.3390/ijms222212516
Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR (2014) SWOG0919: A phase 2 study of Idarubicin and Cytarabine in combination with pravastatin for relapsed acute myeloid Leukaemia. Br J Haematol 167(2):233–237. https://doi.org/10.1111/bjh.13035
Andresen V, Gjertsen BT (2017) Drug repurposing for the treatment of acute myeloid leukemia. Front Med 4:211. https://doi.org/10.3389/fmed.2017.00211
Aslostovar L, Boyd AL, Almakadi M, Collins TJ, Leong DP, Tirona RG, Kim RB, Julian JA, Xenocostas A, Leber B, Levine MN, Foley R, Bhatia M (2018) A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Adv 2(15):1935–1945. https://doi.org/10.1182/bloodadvances.2018015677
Baig MS, Roy A, Saqib U, Rajpoot S, Srivastava M, Naim A, Liu D, Saluja R, Faisal SM, Pan Q, Turkowski K, Darwhekar GN, Savai R (2018) Repurposing Thioridazine (TDZ) as an anti-inflammatory agent. Sci Rep 8:12471. https://doi.org/10.1038/s41598-018-30763-5
Bhagat RT, Butle SR (2021) Drug repurposing: A review. J Pharm Res Int 161–169. https://doi.org/10.9734/jpri/2021/v33i31B31704
Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, Freedman AS, Davids MS, Supko JG, Wu C, Frank DA (2021) Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol 96(4):E95–E98. https://doi.org/10.1002/ajh.26084
Bultum LE, Tolossa GB, Lee D (2022) Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia. PLoS One 17(7):e0270050. https://doi.org/10.1371/journal.pone.0270050
Davis AS (2014) Leukemia: an overview for. Prim Care 89(9):8
Deininger MW (2015) Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educat Book 35:e381–e388. https://doi.org/10.14694/EdBook_AM.2015.35.e381
DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
Dugger SA, Platt A, Goldstein DB (2018) Drug development in the era of precision medicine. Nat Rev Drug Discov 17(3):183–196. https://doi.org/10.1038/nrd.2017.226
Eriksson A, Österroos A, Hassan S, Gullbo J, Rickardson L, Jarvius M, Nygren P, Fryknäs M, Höglund M, Larsson R (2015) Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J 5:e307. https://doi.org/10.1038/bcj.2015.31
Faderl S, O’Brien S, Pui C-H, Stock W, Wetzler M, Hoelzer D, Kantarjian HM (2010) Adult acute lymphoblastic leukemia. Cancer 116(5):1165–1176. https://doi.org/10.1002/cncr.24862
Fattoum J, Cannas G, Elhamri M, Tigaud I, Plesa A, Heiblig M, Plesa C, Wattel E, Thomas X (2015) Effect of age on treatment decision-making in elderly patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(8):477–483. https://doi.org/10.1016/j.clml.2015.02.022
Gorgulla C, Boeszoermenyi A, Wang Z-F, Fischer PD, Coote PW, Padmanabha Das KM, Malets YS, Radchenko DS, Moroz YS, Scott DA, Fackeldey K, Hoffmann M, Iavniuk I, Wagner G, Arthanari H (2020) An open-source drug discovery platform enables ultra-large virtual screens. Nature 580(7805):663–668. https://doi.org/10.1038/s41586-020-2117-z
Goy J, Gillan TL, Bruyere H, Huang SJT, Hrynchak M, Karsan A, Ramadan K, Connors J, Toze CL, Gerrie AS (2017) Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of first-line therapy, but Long overall survival: results of a population-based cohort in British Columbia, Canada. Clin Lymphoma Myeloma Leuk 17(6):382–389. https://doi.org/10.1016/j.clml.2017.04.001
Hallal R, Nehme R, Brachet-Botineau M, Nehme A, Dakik H, Deynoux M, Dello Sbarba P, Levern Y, Zibara K, Gouilleux F, Mazurier F (2020) Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells. J Cell Mol Med 24(17):10052–10062. https://doi.org/10.1111/jcmm.15612
Hamdoun S, Jung P, Efferth T (2017) Drug repurposing of the anthelmintic Niclosamide to treat multidrug-resistant leukemia. Front Pharmacol 8. https://doi.org/10.3389/fphar.2017.00110
Jourdan J-P, Bureau R, Rochais C, Dallemagne P (2020) Drug repositioning: A brief overview. J Pharm Pharmacol 72(9):1145–1151. https://doi.org/10.1111/jphp.13273
Juliusson G, Hough R (2016) Leukemia. Progr Tumor Res 43:87–100. https://doi.org/10.1159/000447076
Lara-Castillo MC, Cornet-Masana JM, Etxabe A, Banús-Mulet A, Torrente MÁ, Nomdedeu M, Díaz-Beyá M, Esteve J, Risueño RM (2016) Repositioning of bromocriptine for treatment of acute myeloid leukemia. J Transl Med 14(1):261. https://doi.org/10.1186/s12967-016-1007-5
Latif T, Chauhan N, Khan R, Moran A, Usmani SZ (2012) Thalidomide and its analogues in the treatment of multiple myeloma. Exp Hematol Oncol 1(1):27. https://doi.org/10.1186/2162-3619-1-27
Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O (2017) In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer J 7(9):e604–e604. https://doi.org/10.1038/bcj.2017.87
Li YY, Jones SJ (2012) Drug repositioning for personalized medicine. Genome Med 4(3):27. https://doi.org/10.1186/gm326
Liu Y, Sun L, Zhang H, Shang L, Zhao Y (2021) Microfluidics for drug development: from synthesis to evaluation. Chem Rev 121(13):7468–7529. https://doi.org/10.1021/acs.chemrev.0c01289
Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR (2020) Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev 29(7):1304–1312. https://doi.org/10.1158/1055-9965.EPI-19-1534
Matchett KB, Grishagin IV, Kettyle L, Dowling C, Ni Chonghaile T, Mills KI, Thompson A (2017) High-throughput screen identification of Albendazole as a novel repurposed drug in acute myeloid Leukaemia. Blood 130:5062. https://doi.org/10.1182/blood.V130.Suppl_1.5062.5062
Mezzatesta C, Abduli L, Guinot A, Eckert C, Schewe D, Zaliova M, Vinti L, Marovca B, Tsai Y-C, Jenni S, Aguade-Gorgorio J, von Stackelberg A, Schrappe M, Locatelli F, Stanulla M, Cario G, Bourquin J-P, Bornhauser BC (2020) Repurposing anthelmintic agents to eradicate resistant leukemia. Blood Cancer J 10(6):1–11. https://doi.org/10.1038/s41408-020-0339-9
Montserrat E, Dreger P (2016) Treatment of chronic lymphocytic leukemia with del(17p)/TP53 mutation: allogeneic hematopoietic stem cell transplantation or BCR-signaling inhibitors? Clin Lymphoma Myeloma Leuk 16(Suppl):S74–S81. https://doi.org/10.1016/j.clml.2016.02.013
Natarajan A, Thangarajan R, Kesavan S (2019) Repurposing drugs by in Silico methods to target BCR kinase domain in chronic myeloid leukemia. Asian Pacific J Cancer Prevent APJCP 20(11):3399–3406. https://doi.org/10.31557/APJCP.2019.20.11.3399
Nehdi A, Samman N, Mashhour A, Alhallaj A, Trivilegio T, Gul S, Reinshagen J, Alaskar A, Gmati G, Abuelgasim KA, Mansour F, Boudjelal M (2021) A drug repositioning approach identifies a combination of compounds as a potential regimen for chronic lymphocytic leukemia treatment. Front Oncol 11:579488. https://doi.org/10.3389/fonc.2021.579488
Nipp RD, Powell E, Chabner B, Moy B (2015) Recognizing the financial burden of cancer patients in clinical trials. Oncologist 20(6):572–575. https://doi.org/10.1634/theoncologist.2015-0068
Nosengo N (2016) New tricks for old drugs. Nature 534(7607):314–316
Nweke EE, Thimiri Govinda Raj DB (2021) Drug sensitivity and drug repurposing platform for cancer precision medicine. Adv Exp Med Biol 1326:47–53. https://doi.org/10.1007/5584_2021_622
Ou Y, Long Y, Ji L, Zhan Y, Qiao T, Wang X, Chen H, Cheng Y (2022) Trends in disease burden of chronic Lymphocytic Leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: A population-based epidemiologic study. Front Oncol:12. https://www.frontiersin.org/articles/10.3389/fonc.2022.840616
Parcha PK, Sarvagalla S, Ashok C, Sudharshan SJ, Dyavaiah M, Coumar MS, Rajasekaran B (2021) Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia. Pharmacol Rep 73(2):615–628. https://doi.org/10.1007/s43440-020-00196-x
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M (2019) Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41–58. https://doi.org/10.1038/nrd.2018.168
Rognan D (2017) The impact of in silico screening in the discovery of novel and safer drug candidates. Pharmacol Ther 175:47–66. https://doi.org/10.1016/j.pharmthera.2017.02.034
Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41. https://doi.org/10.1016/S0140-6736(10)62110-1
Sachlos E, Risueño RM, Laronde S, Shapovalova Z, Lee J-H, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, Levadoux-Martin M, Lee JB, Giacomelli AO, Hassell JA, Fischer-Russell D, Trus MR, Foley R, Leber B, Xenocostas A et al (2012) Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149(6):1284–1297. https://doi.org/10.1016/j.cell.2012.03.049
Serra M, Mai TD, Serra AL, Nguyen M-C, Eisele A, Perié L, Viovy J-L, Ferraro D, Descroix S (2020) Integrated droplet microfluidic device for magnetic particles handling: application to DNA size selection in NGS libraries preparation. Sensors Actuators B Chem 305:127346. https://doi.org/10.1016/j.snb.2019.127346
Shadman M, Mawad R, Dean C, Chen T, Shannon-Dorcy K, Sandhu V, Hendrie PC, Scott BL, Walter RB, Becker PS, Pagel J, Estey EH (2015) Idarubicin, Cytarabine and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol 90(6):483–486. https://doi.org/10.1002/ajh.23981
Singh VK, Chang H-H, Kuo C-C, Shiao H-Y, Hsieh H-P, Coumar MS (2017) Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors. J Biomol Struct Dyn 35(8):1833–1848. https://doi.org/10.1080/07391102.2016.1196462
Skånland SS, Cremaschi A, Bendiksen H, Hermansen JU, Thimiri Govinda Raj DB, Munthe LA, Tjønnfjord GE, Taskén K (2020) An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL. Leukemia 34(2):478–487. https://doi.org/10.1038/s41375-019-0569-7
Sliwoski G, Kothiwale S, Meiler J, Lowe EW (2014) Computational methods in drug discovery. Pharmacol Rev 66(1):334–395. https://doi.org/10.1124/pr.112.007336
Sohraby F, Bagheri M, Aliyar M, Aryapour H (2017) In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study. J Mol Graph Model 74:234–240. https://doi.org/10.1016/j.jmgm.2017.04.005
Sun D, Gao W, Hu H, Zhou S (2022) Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B 12(7):3049–3062. https://doi.org/10.1016/j.apsb.2022.02.002
Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S (2019) Applications of machine learning in drug discovery and development. Nat Rev Drug Discov 18(6):463–477. https://doi.org/10.1038/s41573-019-0024-5
Van den Driessche F, Brackman G, Swimberghe R, Rigole P, Coenye T (2017) Screening a repurposing library for potentiators of antibiotics against Staphylococcus aureus biofilms. Int J Antimicrob Agents 49(3):315–320. https://doi.org/10.1016/j.ijantimicag.2016.11.023
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KGM, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH (2013) Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 121(13):2424–2431. https://doi.org/10.1182/blood-2012-10-462440
Wang F, Liu Z, Zeng J, Zhu H, Li J, Cheng X, Jiang T, Zhang L, Zhang C, Chen T, Liu T, Jia Y (2015) Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy. Leuk Res 39(12):1421–1427. https://doi.org/10.1016/j.leukres.2015.09.016
Xiao Z, Gong R, Chen X, Xiao D, Luo S, Ji Y (2021) Association between serum lactate dehydrogenase and 60-day mortality in Chinese Hakka patients with acute myeloid leukemia: A cohort study. J Clin Lab Anal 35(12):e24049. https://doi.org/10.1002/jcla.24049
Xue H, Li J, Xie H, Wang Y (2018) Review of drug repositioning approaches and resources. Int J Biol Sci 14(10):1232–1244. https://doi.org/10.7150/ijbs.24612
Acknowledgements
We would like to acknowledge the Organisation for Women in Sciences for the Developing world (OWSD) for the doctoral fellowship for Vanelle Larissa Kenmogne. DBTG Raj is funded by NRF Competitive Grant, MRC Self-Initiated Grant, ICGEB Early Career Grant, and Strategic Initiative Funding for Centre from CSIR Parliamentary Grant.
Authors Contribution
Vanelle Larissa Kenmogne wrote the paper together with the contributions from all the authors Ekene Emmanuel Nweke, Mutsa M. Takundwa, Pascaline N. Fru, and Deepak B. Thimiri Govindaraj. All authors read and approved the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kenmogne, V.L., Nweke, E.E., Takundwa, M.M., Fru, P.N., Thimiri Govinda Raj, D.B. (2022). Application of Drug Repurposing-Based Precision Medicine Platform for Leukaemia Patient Treatment. In: Turksen, K. (eds) Cell Biology and Translational Medicine, Volume 19. Advances in Experimental Medicine and Biology(), vol 1410. Springer, Cham. https://doi.org/10.1007/5584_2022_744
Download citation
DOI: https://doi.org/10.1007/5584_2022_744
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-28419-9
Online ISBN: 978-3-031-28420-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)